Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Paul Johnson, Professor
University of Oxford
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Oxford Children'S Hospital
Oxford, Oxfordshire, United Kingdom
- Bristol Royal Hospital for Children
Bristol, United Kingdom
- Addenbrooke'S Hospital
Cambridge, United Kingdom
- the Great North Children'S Hospital
Newcastle upon Tyne, United Kingdom
- Nottingham Children'S Hospital
Nottingham, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Jan 2019
- Primary completion
- 16 Feb 2023
- Completion
- 30 Sept 2026
- Last update posted
- 3 Oct 2025
- Registered enrollment
- 41
- Registry id
- NCT03782636
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.